Advertisements



Aerie Pharmaceuticals stock halted for FDA committee review of glaucoma treatment

Shares of Aerie Pharmaceuticals Inc. were halted for trading Friday, as the U.S. Food and Drugs Administration reviews a new drug application for .....»»

Category: topSource: marketwatchOct 13th, 2017

Spark Therapeutics shares halted as FDA committee reviews gene therapy treatment for eye disease

Spark Therapeutics Inc. shares were halted Thursday as a U.S. Food and Drugs Administration advisory committee meets to review the company's gene therapy treatment for patients with vision loss caused.....»»

Category: topSource: marketwatchOct 12th, 2017

Has Aerie Pharma Put The "Binary Boogeyman" To Bed With Roclatan Phase 3 Data?

Aerie Pharmaceuticals Inc (NASDAQ: AERI) shares were seen up over 29 percent Thursday after the company reported positive Phase III trial data on its glaucoma treatment can Latest Ratings for AERI DateFi.....»»

Category: blogSource: benzingaMay 25th, 2017

Aerie Pharma stock surges 32% on positive late-stage trial results for glaucoma eye drops

Aerie Pharmaceuticals Inc. shares surged as much as 32% in after hours trade Wednesday after the company said its eye drops intended for glaucoma had positive results in a late-stage clinical trial. If Aerie Pharma sees positive safe.....»»

Category: topSource: marketwatchMay 24th, 2017

Merrimack Pharmaceuticals" stock plummets after breast cancer treatment trial halted

Shares of Merrimack Pharmaceuticals Inc. plummeted 30% toward a three-year low in premarket trade Wednesday, after the company said it was halting .....»»

Category: topSource: marketwatchDec 21st, 2016

Regeneron"s stock halted as it receives FDA notice about arthritis treatment

Regeneron Pharmaceuticals Inc. said Friday that it and its partner Sanofi received notice from the Food and Drug Administration that the biologics license application for sarilumab won't be approved until certain concerns are resolved. The FDA's "comple.....»»

Category: topSource: marketwatchOct 28th, 2016

Regeneron"s Stock Halted As It Receives FDA Notice About Arthritis Treatment

Regeneron Pharmaceuticals Inc. said Friday that it and its partner Sanofi received notice from the Food and Drug Administration that the biologics license application for sarilumab won't be approved until certain concerns are resolved......»»

Category: topSource: foxnewsOct 28th, 2016

Aerie Pharmaceuticals Inc Stock May Soar to $96 Soon: RBC Capital

Industry experts contend that Aerie Pharmaceuticals Inc. (NASDAQ:AERI) stock valuation is too low, considering that the company boasts Roclatan, a blockbuster drug candidate for glaucoma. RBC Capital tends to agree with this proposition. In a research not.....»»

Category: topSource: bidnessetcSep 16th, 2016

Aerie Pharmaceuticals Stock May Soar to $96 Soon: RBC Capital

Industry experts contend that Aerie Pharmaceuticals Inc. (NASDAQ:AERI) stock valuation is too low, considering that the company boasts Roclatan, a blockbuster drug candidate for glaucoma. RBC Capital tends to agree with this proposition. In a research not.....»»

Category: topSource: bidnessetcSep 16th, 2016

Aerie Pharma announces secondary offering after big stock jump

Aerie Pharmaceuticals Inc. said late Thursday it was launching a secondary offering of its shares. Aerie shares surged 45% to close at $30.61 Thursday after the drug discovery company announced Wednesday its eye treatment Roclatan performed well in clini.....»»

Category: topSource: marketwatchSep 15th, 2016

Spectrum Pharmaceuticals" stock drops after cancer treatment voted down by FDA committee

Spectrum Pharmaceuticals Inc. said Wednesday that an Food and Drug Administration advisory committee voted that biotechnology company's cancer treatment, Qapzola, did not show substantial evidence of a treatment effect over placebo. The company said the .....»»

Category: topSource: marketwatchSep 14th, 2016

Ironwood Pharma stock jumps 3.5% on positive trials of treatment for type 2 diabetes

Ironwood Pharmaceuticals Inc. shares surged 3.5% in premarket trade Monday, after the company reported positive results in mid-stage.....»»

Category: topSource: marketwatchDec 4th, 2017

Equifax review exonerates executives" stock sales after data breach

Equifax Inc. (NYSE: EFX) said Friday its board has exonerated four executives who sold company shares after a huge data breach was discovered, but before it was made public. A report by a special committee of Equifax's board concludes that “none .....»»

Category: topSource: bizjournalsNov 6th, 2017

Valeant Surrenders Some Early Gains After FDA Approval Of VYZULTA

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) shares are trading higher by 22 cents (1.7 percent) at $11.28 in Friday's session. After Thursday's close, the company announced FDA approval of VYZULTA, for the treatment of open angle glaucoma. read more.....»»

Category: blogSource: benzingaNov 3rd, 2017

Pipeline Bomb: Analysts Review Celgene"s Crohn"s Diseases Failure

Celgene Corporation (NASDAQ: CELG) stock plummeted 10 percent Friday after the company reported that its testing of GED-0301 for treatment of Crohn’s disease has failed to meet its e.....»»

Category: blogSource: benzingaOct 20th, 2017

Aerie (AERI) Up on FDA Review Committee Result for Rhopressa

Zacks.....»»

Category: topSource: redinewsOct 18th, 2017

Aerie (AERI) Up on FDA Review Committee Result for Rhopressa

Shares of .....»»

Category: dealsSource: nytOct 17th, 2017

With nod from panel, Aerie inches toward FDA approval

Aerie Pharmaceuticals (Nasdaq: AERI) – which is in the process of building out its research and development team locally – is moving closer to U.S. Food and Drug Administration approval. On Friday, an FDA advisory committee voted in favor of .....»»

Category: topSource: bizjournalsOct 13th, 2017

Ethics report says NY lawmaker"s actions warrant review

The House Ethics Committee says it's extending its review of a congressman whose stock market trades prompted an advocacy group to request an investigation for possible violation of insider trading or conflict of interest laws......»»

Category: topSource: foxnewsOct 12th, 2017

Ethics panel extends review of New York GOP congressman

The House Ethics Committee says it's extending its review of a congressman whose stock market trades prompted an advocacy group to request an investigation for possible violation of insider trading or conflict of interest laws......»»

Category: topSource: foxnewsOct 12th, 2017

Ethics Committee extends review of New York congressman

The House Ethics Committee says it's extending its review of a congressman whose stock market trades prompted an advocacy group to request an investigation for possible violation of insider trading or conflict of interest laws......»»

Category: topSource: foxnewsOct 12th, 2017